drugset / Trial / NCT00104728
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
Terminated
42 enrolled
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients who are undergoing surgery for stage I, stage II, or stage III non-small cell lung cancer.
Timeline
- Start
- 2004-10
- Primary completion
- 2008-05
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | 250 mg | Oral |